journal article Open Access Oct 07, 2021

Osteosarcoma in Adolescents and Young Adults

Cells Vol. 10 No. 10 pp. 2684 · MDPI AG
View at Publisher Save 10.3390/cells10102684
Abstract
The epidemiology of osteosarcoma in adolescents and young adults (AYA) remains unclear. We aimed to assess and compare the clinical features of osteosarcoma between AYA and other age groups. We retrieved osteosarcoma cases diagnosed between 1999 and 2017 from the Korea Central Cancer Registry. We compared survival trends and clinical characteristics between AYA and other age groups. AYA comprised 43.3% (1309/3022) of the osteosarcoma cases. Compared to other age groups, the male-to-female ratio was highest in AYA (1.61:1). The proportion of tumors located in an extremity was 80.3% in AYA, which was lower than in young children (92.5%) or pubertal children (93.8%) but higher than in adults (55.7%) or the elderly (47.5%). As for treatments, 71.2% of AYA received local treatment and systemic chemotherapy, and 28.8% received only local treatment (surgery: 261, radiotherapy: 9, surgery and radiotherapy: 5). The 5-year overall survival (OS) was lower in AYA (68%) than in young children (78%) or pubertal children (73%) but higher than in adults (47%) or the elderly (25%). When AYA were divided into five subgroups by age, patients aged 15–19 years constituted the largest proportion (45.4%, n = 594). Additionally, the proportion of patients with a non-extremity tumor increased in an age-dependent manner, from 10.3% in AYA aged 15–19 years to 35.3% in AYA aged 35–39 years. OS did not significantly differ among the different age subgroups of AYA. The clinical characteristics and OS of the AYA were more similar to those of children than to those of adults. There is a need for cooperation between pediatric and adult oncologists for effective osteosarcoma treatment in AYA.
Topics

No keywords indexed for this article. Browse by subject →

References
21
[1]
Longhi "Primary Bone Osteosarcoma in the Pediatric Age: State of the Art" Cancer Treat. Rev. (2006) 10.1016/j.ctrv.2006.05.005
[2]
Ferrari "Predictive Factors of Disease-Free Survival for Non-Metastatic Osteosarcoma of the Extremity: An Analysis of 300 Patients Treated at the Rizzoli Institute" Ann. Oncol. (2001) 10.1023/a:1011636912674
[3]
Bacci "Prognostic Factors for Osteosarcoma of the Extremity Treated with Neoadjuvant Chemotherapy: 15-Year Experience in 789 Patients Treated at a Single Institution" Cancer (2006) 10.1002/cncr.21724
[4]
Bacci "Primary High-Grade Osteosarcoma: Comparison Between Preadolescent and Older Patients" J. Pediatr. Hematol. Oncol. (2005) 10.1097/01.mph.0000155860.38641.83
[5]
Meyers "Chemotherapy for Nonmetastatic Osteogenic Sarcoma: The Memorial Sloan-Kettering Experience" J. Clin. Oncol. (1992) 10.1200/jco.1992.10.1.5
[6]
Keegan "Comparison of Cancer Survival Trends in the United States of Adolescents and Young Adults with Those in Children and Older Adults" Cancer (2016) 10.1002/cncr.29869
[7]
Janeway "Outcome for Adolescent and Young Adult Patients with Osteosarcoma: A Report from the Children’s Oncology Group" Cancer (2012) 10.1002/cncr.27414
[8]
Pollock "Registration and Classification of Adolescent and Young Adult Cancer Cases" Pediatr. Blood Cancer (2008) 10.1002/pbc.21462
[9]
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and LIVESTRONG Young Adult Alliance (2006). Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer, Report of the Adolescent and Young Adult Oncology Progress Review Group; NIH Pub. No. 06–6067.
[10]
Children’s Oncology Group, and SEER Program (National Cancer Institute [U.S.]) (2006). Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975–2000.
[11]
Herzog "Overview of Sarcomas in the Adolescent and Young Adult Population" J. Pediatr. Hematol. Oncol. (2005) 10.1097/01.mph.0000161762.53175.e4
[12]
Fritz, A.P., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D.M., and Whelan, S. (2000). International Classification of Diseases for Oncology, World Health Organization. [3rd ed.].
[13]
Daejeon: Statistics Korea (2020, February 28). Available online: http://kosis.kr.
[14]
Young, J.L., Roffers, S., Ries, L., Fritz, A., and Hurlbut, A.A. (2001). SEER Summary Staging Manual −2000: Codes and Coding Instructions.
[15]
Coccia "Overview of Adolescent and Young Adult Oncology" J. Oncol. Pract. (2019) 10.1200/jop.19.00075
[16]
Smeland "Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort" Eur. J. Cancer (2019) 10.1016/j.ejca.2018.11.027
[17]
Fukushima "Descriptive Epidemiology and Outcomes of Bone Sarcomas in Adolescent and Young Adult Patients in Japan" BMC Musculoskelet. Disord. (2018) 10.1186/s12891-018-2217-1
[18]
Park "Cancer Incidence and Survival Among Adolescents and Young Adults in Korea: An Update for 2016" Cancer Res. Treat. (2021) 10.4143/crt.2020.644
[19]
Lee "Osteosarcoma in Korean Children and Adolescents" Korean J. Pediatr. (2015) 10.3345/kjp.2015.58.4.123
[20]
Casali "Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up" Ann. Oncol. (2018) 10.1093/annonc/mdy310
[21]
Bacci "Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity: Intensification of Preoperative Treatment Does Not Increase the Rate of Good Histologic Response to the Primary Tumor or Improve the Final Outcome" J. Pediatr. Hematol. Oncol. (2003) 10.1097/00043426-200311000-00006